{
    "clinical_study": {
        "@rank": "156391", 
        "acronym": "START", 
        "arm_group": [
            {
                "arm_group_label": "TACE+EBRT", 
                "arm_group_type": "Experimental", 
                "description": "Transarterial chemoembolization plus external beam radiation therapy"
            }, 
            {
                "arm_group_label": "Sorafenib", 
                "arm_group_type": "Active Comparator", 
                "description": "Sorafenib 800 mg/day orally"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate and compare the efficacy and safety of trans-arterial chemoembolization plus\n      external beam radiation therapy and sorafenib in patients with hepatocellular carcinoma\n      invading major intrahepatic vessels"
        }, 
        "brief_title": "Transarterial Chemoembolization Plus Radiotherapy or Sorafenib in Hepatocellular Carcinoma With Major Vascular Invasion", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatocellular Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "detailed_description": {
            "textblock": "Current practice guidelines recommend sorafenib for patients with hepatocellular carcinoma\n      invading major intrahepatic vessels. However, recent data suggest that the combination of\n      transarterial chemoembolization and external beam radiotherapy would be effective as\n      sorafenib."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age >19 years\n\n          -  Child-Pugh class A liver function\n\n          -  Performance status: Eastern Cooperative Oncology Group (ECOG) score 0 or 1\n\n          -  Hepatocellular carcinoma (HCC) confirmed by dynamic CT or MRI, or by biopsy\n\n          -  HCC invasion of first or second branch portal vein or hepatic vein or inferior vena\n             cava\n\n          -  Reserved unilateral portal blood flow at least in partial\n\n          -  HCC size larger than 1 cm and less than 50% of total liver volume\n\n          -  No extrahepatic metastasis\n\n          -  Adequate hematopoietic function Hemoglobin \u2265 8.5 g/dL Absolute neutrophil count \u2265\n             750/mm3 Platelet count \u2265 30,000/mm3\n\n          -  Creatinine < 1.5mg/dL\n\n          -  No plan for pregnancy or breast feeding. Active contraception.\n\n          -  Willing to give informed consent\n\n        Exclusion Criteria:\n\n          -  Prior history to or exposure of transarterial chemoembolization, external beam\n             radiation to liver, or sorafenib\n\n          -  Complete obstruction of hepatic outflow\n\n          -  Confirmed extrahepatic metastasis of HCC\n\n          -  HCC occupying more than 50% of liver volume\n\n          -  Uncontrolled ascites of hepatic encephalopathy\n\n          -  Prior liver transplantation\n\n          -  Positive for human immunodeficiency virus (HIV)\n\n          -  Active gastric or duodenal ulcer\n\n          -  Other uncontrolled comorbidities or malignancy\n\n          -  Inability to give informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01901692", 
            "org_study_id": "AMC IRB 2013-0582"
        }, 
        "intervention": [
            {
                "arm_group_label": "TACE+EBRT", 
                "description": "Trans-arterial chemoembolization plus external beam radiation therapy", 
                "intervention_name": "TACE+EBRT", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Sorafenib", 
                "description": "Sorafenib 800 mg/day orally", 
                "intervention_name": "Sorafenib", 
                "intervention_type": "Drug", 
                "other_name": "Nexavar"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sorafenib"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 16, 2014", 
        "location": {
            "contact": {
                "email": "limys@amc.seoul.kr", 
                "last_name": "Young-Suk Lim, MD, PhD", 
                "phone": "82230103190"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "138-736"
                }, 
                "name": "Asan Medical Center"
            }, 
            "investigator": {
                "last_name": "Young-Suk Lim, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Phase II Trial Comparing Transarterial Chemoembolization Plus External Beam Radiotherapy Versus Sorafenib in Patients With Hepatocellular Carcinoma With Major Vascular Invasion", 
        "overall_contact": {
            "email": "limys@amc.seoul.kr", 
            "last_name": "Young-Suk Lim, MD, PhD", 
            "phone": "82230103190"
        }, 
        "overall_official": {
            "affiliation": "Asan Medical Center", 
            "last_name": "Young-Suk Lim, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression-free rate", 
            "safety_issue": "No", 
            "time_frame": "at 3 months after randomization"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01901692"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Asan Medical Center", 
            "investigator_full_name": "Young-Suk Lim", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "at 3 months after randomization"
            }, 
            {
                "measure": "Time-to-failure of treatment", 
                "safety_issue": "No", 
                "time_frame": "within 6 months after randomization"
            }, 
            {
                "measure": "Progression-free survival of patients", 
                "safety_issue": "No", 
                "time_frame": "within 6 months after randomization"
            }, 
            {
                "measure": "Treatment-related adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "within 6 months after randomization"
            }, 
            {
                "measure": "Overall patient survival", 
                "safety_issue": "No", 
                "time_frame": "within 6 months after randomization"
            }
        ], 
        "source": "Asan Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Asan Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}